[View original text]

On 2nd of July, It is said that AIDOT (CEO Jae-hoon Jeong) was selected as a special zone operator capable of early screening patients with chronic alcoholic liver disease with AI 

through analysis of human-derived materials at Gangwon Precision Medical Industry Regulatory Freedom Zone which finally approved by the Regulatory Freedom Special Zone 

Committee presided over by Prime Minister Boo-gyum Kim.

AIDOT conducted precedent research for over a year with Professor Ki-tae Suk's team at the Department of Gastroenterology at Hallym University Chuncheon Sacred Heart Hospital.

With this regulatory special zone project, a special regulation was applied, enabling the secondary use of human-derived information collected and analyzed through microbiome 

analysis.Accordingly, it plans to finish upgrading the solution to the stage where it can be commercialized immediately and promote certification by the Ministry of Food and Drug 

Safety in Korea.

Among the special cases for the regulation of precision medicine in Gangwon Province, the new medical technology evaluation period is also postponed, and the special case for 

demonstration will proceed immediately after certification by the Ministry of Food and Drug Safety. Based on these achievements, the goal is to achieve global commercialization 

early by mobilizing overseas networks.

Professor Ki-tae Suk of the Department of Gastroenterology at Hallym University said, "In the course of previous research with AIDOT, we confirmed that the risk of liver disease can 

be detected early through the process of effectively pre-processing big data from microbiome analysis."

He emphasized, “This will lead to innovative development in terms of early detection of liver disease, and in particular, it will be able to greatly contribute to reducing all social costs 

caused by alcoholic liver disease.”

AIDOT CEO Jae-hoon Jeong said, “This project will be the core medical business in AIDOT’s pipeline.By defining a specific target disease, early detection of alcoholic liver disease risk group, in the globally verified and rapidly developing microbiome treatment market,

AIDOT will commercialize the first AI-based microbiome genome analysis solution and dominate the global market."

He added, “Through certification by the Ministry of Food and Drug Safety in Korea, efforts will be made to diagnose and predict alcoholic liver disease only with a simple stool test at 

primary and secondary medical institutions.”

02nd, Jul. 2021. / Robot News  Reporter Kyung-il Park